Addition of a cysteine to glucagon-like peptide-1 (GLP-1) conjugates GLP-1 to albumin in serum and prolongs GLP-1 action in vivo

Regulatory Peptides

Volumn 164, Issue 2-3, 2010, Pages 83-89

  Wu, Ye Lin ^a   Huang, Jing ^a   Xu, Jin ^a   Liu, Jian ^a   Feng, Zhen ^a   Wang, Yang ^a   Lai, Yuping ^a   Wu, Zi Rong ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Albumin conjugation; Diabetic treatment; Glucagon like peptide 1; Protease degradation

Indexed keywords

ANTIDIABETIC AGENT; CYCLIC AMP; CYSTEINE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; PROTEINASE; RECOMBINANT GLUCAGON LIKE PEPTIDE 1; SERUM ALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL STRAIN; CONTROLLED STUDY; COVALENT BOND; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG PURIFICATION; DRUG SYNTHESIS; ESCHERICHIA COLI; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HORMONE ACTION; IN VITRO STUDY; IN VIVO STUDY; INSULIN BLOOD LEVEL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; SINGLE DRUG DOSE;

ANIMALS; CELL LINE; CYSTEINE; GLUCAGON-LIKE PEPTIDE 1; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN; MICE; NEURITES; PC12 CELLS; PROTEIN BINDING; RATS; RECOMBINANT PROTEINS; SERUM ALBUMIN;

ESCHERICHIA COLI; MUS;

EID: 77955846737     PISSN: 01670115     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.regpep.2010.05.003     Document Type: Article

References (28)

1. Wang Q., Li L., Xu E., Wong V., Rhodes C., Brubaker P.L. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004, 47:478-487.
2. Drucker D.J. The biology of incretin hormones. Cell Metab 2006, 3:153-165.
3. Lee S.H., Lee S., Youn Y.S., Na D.H., Chae S.Y., Byun Y., Lee K.C. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem 2005, 16:377-382.
4. Perry T., Lahiri D.K., Chen D., Zhou J., Shaw K.T., Egan J.M., Greig N.H. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002, 300:958-966.
5. Qin Z., Sun Z., Huang J., Hu Y., Wu Z., Mei B. Mutated recombinant human glucagon-like peptide-1 protects SH-SY5Y cells from apoptosis induced by amyloid-beta peptide (1-42). Neurosci Lett 2008, 444:217-221.
6. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
7. Youn Y.S., Chae S.Y., Lee S., Jeon J.E., Shin H.G., Lee K.C. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: insulinotropic activity, glucose-stabilizing capability, and proteolytic stability. Biochem Pharmacol 2007, 73:84-93.
8. Nielsen L.L., Baron A.D. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 2003, 4:401-405.
9. Green B.D., Lavery K.S., Irwin N., O'Harte F.P., Harriott P., Greer B., Bailey C.J., Flatt P.R. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice. J Pharmacol Exp Ther 2006, 318:914-921.
10. Knudsen L.B., Nielsen P.F., Huusfeldt P.O., Johansen N.L., Madsen K., Pedersen F.Z., Thogersen H., Wilken M., Agerso H. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 2000, 43:1664-1669.
11. Kim J.G., Baggio L.L., Bridon D.P., Castaigne J.P., Robitaille M.F., Jette L., Benquet C., Drucker D.J. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003, 52:751-759.
12. O'Harte F.P., Mooney M.H., Lawlor A., Flatt P.R. N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim Biophys Acta 2000, 1474:13-22.
13. Green B.D., Mooney M.H., Gault V.A., Irwin N., Bailey C.J., Harriott P., Greer B., O'Harte F.P., Flatt P.R. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 2004, 180:379-388.
14. McKillop A.M., Duffy N.A., Lindsay J.R., O'Harte F.P., Bell P.M., Flatt P.R. Decreased dipeptidyl peptidase-IV activity and glucagon-like peptide-1(7-36)amide degradation in type 2 diabetic subjects. Diab Res Clin Pract 2008, 79:79-85.
15. Al-Majed H.T., Jones P.M., Persaud S.J., Sugden D., Huang G.C., Amiel S., Whitehouse B.J. ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans. J Endocrinol 2004, 180:155-166.
16. Drucker D.J., Philippe J., Mojsov S., Chick W.L., Habener J.F. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A 1987, 84:3434-3438.
17. Kieffer T.J., McIntosh C.H., Pederson R.A. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 1995, 136:3585-3596.
18. Arulmozhi D.K., Portha B. GLP-1 based therapy for type 2 diabetes. Eur J Pharm Sci 2006, 28:96-108.
19. Leger R., Robitaille M., Quraishi O., Denholm E., Benquet C., Carette J., van Wyk P., Pellerin I., Bousquet-Gagnon N., Castaigne J.P., Bridon D. Synthesis and in vitro analysis of atrial natriuretic peptide-albumin conjugates. Bioorg Med Chem Lett 2003, 13:3571-3575.
20. Kratz F., Muller-Driver R., Hofmann I., Drevs J., Unger C. A novel macromolecular prodrug concept exploiting endogenous serum albumin as a drug carrier for cancer chemotherapy. J Med Chem 2000, 43:1253-1256.
21. Agerso H., Jensen L.B., Elbrond B., Rolan P., Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002, 45:195-202.
22. Sogami M., Era S., Nagaoka S., Kuwata K., Kida K., Shigemi J., Miura K., Suzuki E., Muto Y., Tomita E., et al. High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. II. J Chromatogr 1985, 332:19-27.
23. Etoh T., Miyazaki M., Harada K., Nakayama M., Sugii A. Rapid analysis of human serum albumin by high-performance liquid chromatography. J Chromatogr 1992, 578:292-296.
24. Era S., Hamaguchi T., Sogami M., Kuwata K., Suzuki E., Miura K., Kawai K., Kitazawa Y., Okabe H., Noma A., et al. Further studies on the resolution of human mercapt- and nonmercaptalbumin and on human serum albumin in the elderly by high-performance liquid chromatography. Int J Pept Protein Res 1988, 31:435-442.
25. Coleman R.D., Kim T.W., Gotto A.M., Yang C.Y. Determination of cysteine on low-density lipoproteins using the fluorescent probe, 5-iodoacetamidofluoresceine. Biochim Biophys Acta 1990, 1037:129-132.
26. Yang C.Y., Kim T.W., Weng S.A., Lee B.R., Yang M.L., Gotto A.M. Isolation and characterization of sulfhydryl and disulfide peptides of human apolipoprotein B-100. Proc Natl Acad Sci U S A 1990, 87:5523-5527.
27. Smith D.E., Mosher D.F., Johnson R.B., Furcht L.T. Immunological identification of two sulfhydryl-containing fragments of human plasma fibronectin. J Biol Chem 1982, 257:5831-5838.
28. Morii M., Odani S., Koide T., Ikenaka T. Human alpha1-antitrypsin. Characterization and N- and C-terminal sequences. J Biochem 1978, 83:269-277.